Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for pediatric lupus nephritis (multicenter observational)
ChiCTR2200066257Phase 4Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Response rate (global clinical and laboratory response) at 12 months. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2200066257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066257.